Skip to contentN
Northwest Biotherapeutics Inc
N
NWBONorthwest Biotherapeutics Inc Q3 2025 · 10-Q
Revenue$200.00K$200.00K−44.0% vs Q3 2024 Net Income-$26.83M-$26.83MN/M vs Q3 2024 EPS Diluted-$0.02-$0.02N/M vs Q3 2024 Operating Income-$14,320,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Northwest Biotherapeutics Inc · CIK 1072379 · Engraved from SEC EDGAR
derived
Free Cash Flowderived-$14,095,000N/M Margins · derivedOperating margin-7160.0%−3014.1 pt vs Q3 2024
Net margin-13414.5%−7987.6 pt vs Q3 2024
ended Sep 30, 2025 · filed Nov 14, 2025 · 45 d after period end